On December 6, 2023, CASI Pharmaceuticals, Inc. entered into an Exclusive Distribution Agreement, effective as of December 6, 2023, with China National Medicines Corporation Ltd. ("CNMC") and CASI Pharmaceuticals (China) Co. Ltd. ("CASI China"), a wholly owned subsidiary of the Company established under the laws of the people's Republic of China. Under the terms of the Agreement, CASI appointed CNMC on an exclusive basis as its sole distributor for the sale of Pralatrexate for Injection (Folotyn) (the "Product") in the territory of the People's Republic of China (excluding Hong Kong SAR, Taiwan and Macau) (the "Territory") during the term of one year, subject to certain terms and conditions.

CNMC will use its best efforts to distribute and sell the Product to the maximum number of customers in the Territory. CNMC may appoint sub-distributors of its choice in furtherance of this goal provided that CASI has been notified in writing and received the due diligence or any other information of the sub-distributor as CASI requests. The Agreement also contains terms and conditions with respect to pharmacovigilance and reporting, limited warranty and limitations of liabilities, indemnification and compensation as well as other customary provisions.

CASI China is authorized to coordinate and communicate with parties to the Agreement and provide supports for the performance of the Agreement within the Territory.